SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: ETIOLOGY, PATHOGENESIS, CLASSIFICATION, CLINICS, DIAGNOSIS, TREATMENT. MODERN ASPECTS. LITERATURE REVIEW

Koniushevska A. A., Vaizer N. V., Taran I. D.

LITERATURE REVIEWS

Scentific article

The article is devoted to the current state of the problem of Systemic Juvenile Idiopathic Arthritis. A historical insight into the concept of the disease and its definitions is made. The literature review of the modern concept of epidemiology, etiology, pathogenesis, classification, course, clinic of Systemic Juvenile Idiopathic Arthritis is presented. It is emphasized that the diagnosis of Systemic Juvenile Idiopathic Arthritis is the most difficult, especially when the joint syndrome is absent or delayed, or mild, or may have arthralgia, and the clinical picture is dominated by hectic fever, rash and internal organ damage. The modern criteria for the diagnosis of Systemic Juvenile Idiopathic Arthritis are presented. A comparative characterization of the ILAR and Yamaguchi criteria was performed. Yamaguchi’s criteria do not make arthritis mandatory for the diagnosis and treatment of systemic juvenile idiopathic arthritis, which makes these criteria more sensitive, facilitates early and timely diagnosis and timely treatment.The latest data on the possibility of treating the disease are highlighted in detail: glucocorticosteroids, nonsteroidal anti-inflammatory drugs, immunosuppressants, genetically engineered biological drugs. Particular attention is paid to international experience in the use of genetically engineered biological drugs in the treatment of Systemic Juvenile Idiopathic Arthritis: IL-6 inhibitor – tocilizumab, IL-1 inhibitors – anakinra, canakimumab, and in case of ineffectiveness of IL-6, IL-1, – rituximab – chimeric monoclonal antibodies to CD20 + (B lymphocytes). The prospects for the use of Jak inhibitors in patients with refractory Systemic Juvenile Idiopathic Arthritis are discussed. The appropriate appointment of aggressive therapy in the early stages of Systemic Juvenile Idiopathic Arthritis can prevent complications, prevent the progression of the pathological process and the formation of deforming arthritis with early disability of the child. It is concluded that Systemic Juvenile Idiopathic Arthritis is a severe serious pathology in children and requires further in-depth study of this problem, optimization of the diagnostic algorithm and individual approach to treatment.

Systemic Juvenile Idiopathic Arthritis, children, clinic, diagnosis, treatment.

1. Baranov AA, Alekseeva EI, redaktory. Klinicheskie rekomendacii dlja pediatrov. Detskaja revmatologija. Revmaticheskie bolezni u detej. Moskva: Pediatr; 2016. 144 s. [in Russian].
2. Bojko YаЄ. Nomenklatura ta klasifіkacіya yuvenіl’nogo іdіopatichnogo artritu. Ukraїns’kij revmatologіchnij zhurnal. 2017;1(67):52-5. [in Ukrainian].
3. Bojko YaЄ, redaktor. Yuvenіl’nij іdіopatichnij artrit. L’vіv: Svіt; 2019. 223 s. [in Ukrainian].
4. Berezhnij VV, Marushko TV, German OB, Marushko ЄYu. Tocilіzumab u lіkuvannі yuvenіl’nogo revmatoїdnogo artritu. Zdorov’e rebenka. 2015;61(2):151-57. [in Ukrainian].
5. Geppe NA, Podchernyaeva NS, Lyskina GA, redaktory. Rukovodstvo po detskoj revmatologii. Moskva: GEOTAR-Media; 2011. 720 s. [in Russian].
6. Petty RE, Laxer RM, Lindsley CB, Wedderburn L, editors. Textbook of Pediatric Rheumatology. 7th ed. Elsevier; 2016. 746 p. DOI: https:// doi.org/10.1016/C2012-0-00349-3.
7. Rejtmaєr MJ. Yuvenіl’nij revmatoidnij artrit: suchasnі termіnologіchnі, klasifіkacіjnі ta dіagnostichnі rozbіzhnostі. Arhіv klіnіchnoї medicini. 2012;2:91-4. [in Ukrainian].
8. Bogmat LF, Shevchenko NS. Sistemnyj variant yuvenil’nogo idiopaticheskogo (revmatoidnogo) artrita u detej i podrostkov: novoe v lechenii (obzor literatury i sobstvennye nablyudeniya). Zdorov’ye Rebenka. 2017;12(4):505-13. DOI: 10.22141/2224-0551.12.4.2017.107633. [in Ukrainian].
9. Volosyanko AB, Rejtmaєr MJ, Іvanishin LYа. Іstorіya termіnu «yuvenіl’nij revmatoїdnij artrit», jogo evolyucіya ta suchasne traktuvannya. Suchasna pedіatrіya. 2020;2(106):83-8. DOI: 10.15574/SP.2020.106.83. [in Ukrainian].
10. Nigrovic PA, Raychaudhuri S, Thompson SD. Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018 Jan;70(1):7-17. DOI: 10.1002/art.40350.
11. Kostik MM, Isupova EA, Chikova IA, Dubko MF, Masalova VV, Snegireva LS, et al. Ocenka effektivnosti i bezopasnosti terapii tocilizumabom pacientov s sistemnoj formoj yuvenil’nogo idiopaticheskogo artrita: rezul’taty retrospektivnogo nablyudeniya. Sovremennaya revmatologiya. 2017;11(4):30-9. [in Russian].
12. Nikishina IP, Kaleda MI. Sovremennaya farmakoterapiya sistemnogo yuvenil’nogo artrita. Nauchno-prakticheskaya revmatologiya. 2015;53(1):84-93. DOI: http://dx.doi.org/10.14412/1995-4484-2015-84-93. [in Russian].
13. Lomakina OL. Obshcherossijskij registr pacientov s sistemnym yuvenil’nym idiopaticheskim artritom- effektivnyj instrument monitoringa zabolevaniya i medicinskoj pomoshchi [avtoreferat]. Moskva: Nacional’nyj nauchno-prakticheskij centr zdorov’ya detej; 2017. 24 s. [in Russian].
14. Isupova EA. Yuvenilnii artrit s sistemnim nachalom: differencialnaya diagnostika jizneugrojayuschih sostoyanii i individualizaciya programm blokirovki interleikina-6 [dysertatsiia]. Sankt-Peterburg: Sankt Peterburgskii gos. ped. med. un-t; 2019. 147 s. [in Russian].
15. Valieva SI. Novye tekhnologii v lechenii sistemnogo yuvenil’nogo idiopaticheskogo artrita [avtoreferat]. Moskva: Moskovskij gos. medikostomatologicheskij un-t im. Evdokimova A.I; 2014. 49 s. [in Russian].
16. Spivakovskiy YM, Chernenkov YV, Spivakovskaya AY, Skupova OV, Shulgina EN. Klinicheskoye nablyudeniye primeneniya totsilizumaba u patsiyenta s sistemnym variantom yuvenil’nogo idiopaticheskogo artrita. Pediatricheskaya farmakologiya [Internet]. 2015;12(6):672-6. Dostupno: https://www.pedpharma.ru/jour/article/view/1371/737. DOI: 10.15690/pf.v 12i6.1491. [in Russian].
17. Salugina SO. Nozologicheskaya diagnostika yuvenil’nogo artrita na raznyh etapah nablyudeniya. Sovremennaya revmatologiya. 2010;3:22-8. [in Russian].
18. Still GF. On a form of chronic joint disease in children. Clin Orthop Relat Res. 1990 Oct;(259):4-10.
19. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12:56-9. DOI: 10.1016/j.autrev.2012.07.022.
20. Vіnnic’kij nacіonal’nij medichnij unіversitet іm. M.І. Pirogova. Metodichnі vkazіvki dlya samostіjnoї roboti studentіv pri pіdgotovcі do praktichnogo (semіnars’kogo) zanyattya «Diferencіjna dіagnostika suglobovogo sindromu u dіtej. Yuvenіl’nij revmatoїdnij artrit, reaktivnі artriti». Vinnytsya: Vіnnic’kij nacіonal’nij medichnij unіversitet іm. M.І. Pirogova; 2014. 50 s. [in Ukrainian].
21. Albaker A. Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know? Open Journal of Pediatrics. 2020 Dec;10(4):769-801. DOI: 10.4236/ojped.2020.104078.
22. Torosyan GG, Zholobova ES, Glazyrina AA, Koltunov IE. Slozhnosti diagnostiki sistemnogo yuvenil’nogo idiopaticheskogo artrita. Pediatriya. 2016;95(5):162-5. [in Russian].
23. Kaleda MI, Nikishina IP. Effektivnost’ i bezopasnost’ tocilizumaba u detej s sistemnym variantom yuvenil’nogo artrita v klinicheskoj praktike. Nauchno-prakticheskaya revmatologiya [Internet]. 2015;53(2):204-13. DOI: https:// doi.org/10.14412/1995-4484-2015-204-213. [in Russian].
24. Lomakina ОL, Alekseyeva YeI, Valieva SI, Bzarova ТМ, Denisova RV, Sleptsova ТV. Klinicheskij sluchaj primeneniya tocilizumaba u pacientki s rannim debyutom sistemnogo yuvenil’nogo idiopaticheskogo artrita. Voprosy sovremennoi pediatrii. 2014;13(5):100-3. [in Russian].
25. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Klinicheskie rekomendacii Yunosheskij artrit s sistemnym nachalom M08.2. Moskva: Ministerstvo zdravookhraneniya Rossiyskoy Federatsii; 2021. 230 s. [in Russian].
26. Alekseeva EI, Lomakina OL, Valieva SI, Bzarova TM. Obzor mezhdunarodnyh registrov pacientov s sistemnym yuvenil’nym idiopaticheskim artritom. Voprosy sovremennoj pediatrii. 2017;16(1):18-23. DOI: https://doi.org/10.15690/vsp.v16i1.1690. [in Russian].
27. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465-82. DOI: 10.1002/acr.20460.
28. Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016 Sep;75(9):1654- 60. DOI: 10.1136/annrheumdis-2015-207818.
29. Bojko YaЄ. Kal’protektіn krovі (MRP-8/MRP-14) – chutlivij bіomarker dіagnostiki sistemnogo yuvenіl’nogo іdіopatichnogo artritu. Ukraїns’kij revmatologіchnij zhurnal. 2016;3(65):11-13. [in Ukrainian].
30. Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas JP, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci USA. 2015;112:15970-5. DOI: 10.1073/pnas.1520779112.
31. Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-13. DOI: 10.1136/annrheumdis-2016-210324.
32. Stashkevich DS, Filippova YuYu, Burmistrova AL. Aktual’nye voprosy immunologii: sistema citokinov, biologicheskoe znachenie, geneticheskij polimorfizm, metody opredeleniya. Chelyabinsk: Cicero; 2016. 82 s. [in Russian].
33. Kaleda MI, Nikishina IP. Lechenie sistemnogo varianta yuvenil’nogo idiopaticheskogo artrita s primeneniem genno-inzhenernyh biologicheskih preparatov v klinicheskoj praktike. Pediatriya. 2015;94(2):116-24. [in Russian].
34. Gulati K, Guhathakurta S, Joshi J, Rai N, Ray A. Cytokines and their Role in Health and Disease: A Brief Overview. MOJ Immunol. 2016;4(2):00121. DOI: 10.15406/moji.2016.04.00121.
35. Nasonov EL. Dostizheniya revmatologii v XXI v. Nauchno-prakticheskaya revmatologiya. 2014;52(2):133-40. DOI: https://doi. org/10.14412/1995-4484-2014-133-140. [in Russian].
36. Fedorov ES, Salugina SO, Kuz’mina NN. Rol’ citokinovoj seti v regulyacii vospaleniya pri razlichnyh variantah yuvenil’nogo artrita. Nauchno-prakticheskaya revmatologiya. 2009;47(3):74-89. DOI: https://doi.org/10. 14412/1995-4484-2009-1316. [in Russian].
37. Nasonov EL, redactor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita. Moskva: IMA-PRESS; 2013. 522 s. [in Russian].

«Bulletin of problems biology and medicine» Issue 1 (163), 2022 year, 50-61 pages, index UDK 616.72-002-021.3-053.2-092-07-08-048.445

10.29254/2077-4214-2022-1-163-50-61